SEC Sues InterMune Options Buyers Over Inside Tips
The U.S. Securities and Exchange Commission has filed suit against unknown InterMune Inc. stock options purchasers, contending that they may have profited from inside information about the biotechnology company's lung disease...To view the full article, register now.
Already a subscriber? Click here to view full article